Agrahari R, Mohanty S, Vishwakarma K, Nayak SK, Samantaray D, Mohapatra S (2021) Update vision on COVID-19: structure, immune pathogenesis, treatment and safety assessment. Sensors International 2:100073. https://doi.org/10.1016/j.sintl.2020.100073

Article  PubMed  Google Scholar 

Alandijany TA, El-Kafrawy SA, Tolah AM, Sohrab SS, Faizo AA, Hassan AM, Alsubhi TL, Othman NA, Azhar EI (2020) Development and optimization of in-house ELISA for detection of human igg antibody to SARS-CoV-2 full length spike protein. Pathogens 9:1–11. https://doi.org/10.3390/pathogens9100803

Article  CAS  Google Scholar 

Amanat F, Stadlbauer D, Strohmeier S, O Nguyen TH, Chromikova V, McMahon M, Jiang K, Asthagiri Arunkumar G, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Amarilis Lugo L, Milunka Kojic E, Stoever J, H Liu ST, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F (2020) A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. https://doi.org/10.1038/s41591-020-0913-5

Ayón-Núñez DA, Cervantes-Torres J, Cabello-Gutiérrez C, Rosales-Mendoza S, Rios-Valencia D, Huerta L, Bobes RJ, Carrero JC, Segura-Velázquez R, Fierro NA, Hernández M, Zúñiga-Ramos J, Gamba G, Cárdenas G, Frías-Jiménez E, Herrera LA, Fragoso G, Sciutto E, Suárez-Güemes F, Laclette JP (2022) An RBD-based diagnostic method useful for the surveillance of protective immunity against SARS-CoV-2 in the population. Diagnostics 12.https://doi.org/10.3390/diagnostics12071629

Bonanni P, Cantón R, Gill D, Halfon P, Liebert UG, Crespo KAN, Martín JJP, Trombetta CM (2021) The role of serology testing to strengthen vaccination initiatives and policies for COVID-19 in Europe. Covid 1:20–38. https://doi.org/10.3390/covid1010004

Article  CAS  Google Scholar 

Byrnes JR, Zhou XX, Lui I, Elledge SK, Glasgow JE, Lim SA, Loudermilk RP, Chiu CY, Wang TT, Wilson MR, Leung KK, Wells JA (2020) Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptor-binding domain compete for ACE2 binding. mSphere 5. https://doi.org/10.1128/msphere.00802-20

Castro R, Nobre LS, Eleutério RP, Thomaz M, Pires A, Monteiro SM, Mendes S, Gomes RA, Clemente JJ, Sousa MFQ, Pinto F, Silva AC, Freitas MC, Lemos AR, Akpogheneta O, Kosack L, Bergman ML, Duarte N, Matoso P, Costa J, Bandeiras TM, Gomes-Alves P, Gonçalves CP, Demengeot J, Alves PM (2021) Production of high-quality SARS-CoV-2 antigens: impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance. Biotechnol Bioeng 118:2202–2219. https://doi.org/10.1002/bit.27725

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, Pérez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, Álvarez DE, Pasquevich KA, Cassataro J (2022) A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations containing alum increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection in mice. Front Immunol 13:1–17. https://doi.org/10.3389/fimmu.2022.844837

Article  CAS  Google Scholar 

Derringer G, Suich R (1980) Simultaneous optimization of several response variables. J Qual Technol 12:214–219. https://doi.org/10.1080/00224065.1980.11980968

Article  Google Scholar 

Faizo AA, Alandijany TA, Abbas AT, Sohrab SS, El-Kafrawy SA, Tolah AM, Hassan AM, Azhar EI (2021) A reliable indirect ELISA protocol for detection of human antibodies directed to SARS-CoV-2 Np protein. Diagnostics 11:1–12. https://doi.org/10.3390/diagnostics11050825

Article  CAS  Google Scholar 

FDA (2022) SARS-CoV-2 viral mutations: impact on COVID test Dashboard. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests. Accessed 28 September 2022

Fernandes-Siqueira LO, Ferreira FAP, Sousa BG, Mebus-Antunes NC, Neves-Martins TC, Almeida FCL, Ferreira GC, Salmon D, Wermelinger LS, da Poian AT (2022) On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination. Sci Rep 12. https://doi.org/10.1038/s41598-022-14294-8

Fernández-Barat L, López-Aladid R, Torres A (2020) The value of serology testing to manage SARS-CoV-2 infections. Eur Respir J 56:2–4. https://doi.org/10.1183/13993003.02411-2020

Article  CAS  Google Scholar 

Fukuda IM, Pinto CFF, Moreira CDS, Saviano AM, Lourenço FR (2018) Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Braz J Pharm Sci 54:1–16. https://doi.org/10.1590/s2175-97902018000001006

Article  CAS  Google Scholar 

GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, Leijten L, Rokx C, Rijnders B, Rahamat-Langendoen J, van den Akker JPC, van Kampen JJA, van der Eijk AA, van Binnendijk RS, Haagmans B, Koopmans M (2020) An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 11:1–5. https://doi.org/10.1038/s41467-020-17317-y

Article  CAS  Google Scholar 

Goicoechea HC (2018) Chapter 10: experimental design. In: Fingerprinting techniques in food authentication and traceability. pp 187–206

Gourbatsi E, Povey JF, Smales CM (2018) The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv. Biotechnol Lett 40:33–46. https://doi.org/10.1007/s10529-017-2443-x

Article  CAS  PubMed  Google Scholar 

Grant OC, Montgomery D, Ito K, Woods RJ (2020) Analysis of the SARS - CoV - 2 spike protein glycan shield reveals implications for immune recognition. Sci Rep 1–11. https://doi.org/10.1038/s41598-020-71748-7

Gstöttner C, Zhang T, Resemann A, Ruben S, Pengelley S, Suckau D, Welsink T, Wuhrer M, Domínguez-Vega E (2022) Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. 28:56. https://doi.org/10.1021/acs.analchem.1c00893

Harlow E, Lane D (1988) Antibodies A LABORATORY MANUAL. Cold Spring Harbor Laboratory Press, New York, USA, Ch 5

Hassine HI (2022) Covid-19 vaccines and variants of concern: A review. Rev Med Virol 32(4):e2313. https://doi.org/10.1002/rmv.2313

Ibrahim EH, Ghramh HA, Kilany M (2021) Development of in-house ELISAs for the detection of anti-SARS-CoV-2 RBD and N IgG and IgM antibodies in biological samples. J King Saud Univ Sci 33. https://doi.org/10.1016/j.jksus.2021.101439

Klausberger M, Duerkop M, Haslacher H, Wozniak-Knopp G, Cserjan-Puschmann M, Perkmann T, Lingg N, Aguilar PP, Laurent E, de Vos J, Hofner M, Holzer B, Stadler M, Manhart G, Vierlinger K, Egger M, Milchram L, Gludovacz E, Marx N, Köppl C, Tauer C, Beck J, Maresch D, Grünwald-Gruber C, Strobl F, Satzer P, Stadlmayr G, Vavra U, Huber J, Wahrmann M, Eskandary F, Breyer MK, Sieghart D, Quehenberger P, Leitner G, Strassl R, Egger AE, Irsara C, Griesmacher A, Hoermann G, Weiss G, Bellmann-Weiler R, Loeffler-Ragg J, Borth N, Strasser R, Jungbauer A, Hahn R, Mairhofer J, Hartmann B, Binder NB, Striedner G, Mach L, Weinhäusel A, Dieplinger B, Grebien F, Gerner W, Binder CJ, Grabherr R (2021) A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests. EBioMedicine 67. https://doi.org/10.1016/j.ebiom.2021.103348

Konrath KM, Liaw K, Wu Y, Zhu X, Walker SN, Xu Z, Schultheis K, Chokkalingam N, Chawla H, Du J, Tursi NJ, Moore A, Adolf-Bryfogle J, Purwar M, Reuschel EL, Frase D, Sullivan M, Fry B, Maricic I, Andrade VM, Iffland C, Crispin M, Broderick KE, Humeau LMPF, Patel A, Smith TRF, Pallesen J, Weiner DB, Kulp DW (2022) Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Rep 38. https://doi.org/10.1016/j.celrep.2022.110318

Krähling V, Halwe S, Rohde C, Becker D, Berghöfer S, Dahlke C, Eickmann M, Ercanoglu MS, Gieselmann L, Herwig A, Kupke A, Müller H, Klein F, Keller C, Becker S, Neubauer-r P (2021) Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies. J Immunol Methods 490:1–10

Article  Google Scholar 

Liu G, Rusling JF (2021) COVID-19 Antibody Tests and Their Limitations. ACS Sens 6:593–612. https://doi.org/10.1021/acssensors.0c02621

Article  CAS  PubMed  Google Scholar 

Malm M, Kuo CC, Barzadd MM, Mebrahtu A, Wistbacka N, Razavi R, Volk AL, Lundqvist M, Kotol D, Tegel H, Hober S, Edfors F, Gräslund T, Chotteau V, Field R, Varley PG, Roth RG, Lewis NE, Hatton D, Rockberg J (2022) Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins. Metab Eng 72:171–187. https://doi.org/10.1016/j.ymben.2022.03.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehalko J, Drew M, Snead K, Denson JP, Wall V, Taylor T, Sadtler K, Messing S, Gillette W, Esposito D (2021) Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays. Protein Expr Purif 179. https://doi.org/10.1016/j.pep.2020.105802

Mehdi F, Chattopadhyay S, Thiruvengadam R, Yadav S, Kumar M, Sinha SK, Goswami S, Kshetrapal P, Wadhwa N, Chandramouli Natchu U, Sopory S, Koundinya Desiraju B, Pandey AK, Das A, Verma N, Sharma N, Sharma P, Bhartia V, Gosain M, Lodha R, Lamminmäki U, Shrivastava T, Bhatnagar S, Batra G (2021) Development of a fast SARS-CoV-2 IgG ELISA, based on receptor-binding domain, and its comparative evaluation using temporally segregated samples from RT-PCR positive individuals. Front Microbiol 11:1–12. https://doi.org/10.3389/fmicb.2020.618097

Article  Google Scholar 

Mufarrege EF, Antuña S, Etcheverrigaray M, Kratje R, Prieto C (2014) Development of lentiviral vectors for transient and stable protein overexpression in mammalian cells. A new strategy for recombinant human FVIII (rhFVIII) production. Protein Expr Purif 95:50–56. https://doi.org/10.1016/j.pep.2013.11.005

Article  PubMed  Google Scholar 

Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–199. https://doi.org/10.1016/0378-1119(91)90434-D

Article  CAS  PubMed  Google Scholar 

O’Flaherty R, Bergin A, Flampouri E, Mota LM, Obaidi I, Quigley A, Xie Y, Butler M (2020) Mammalian cell culture for production of recombinant proteins: a review of the critical steps in their biomanufacturing. Biotechnol Adv 43:107552. https://doi.org/10.1016/j.biotechadv.2020.107552

Article  CAS  PubMed  Google Scholar 

Ojeda DS, Lopez Ledesma MMG, Pallarés HM, Costa Navarro GS, Sanchez L, Perazzi B, Villordo SM, Alvarez DE, Echavarria M, Oguntuyo KY, Stevens CS, Lee B, Carradori J, Caramelo JJ, Yanovsky MJ, Gamarnik AV, Long-Ueira Y, Polo ML, Salvatori M, Azzolina S, Ghiglione Y, Salomon H, Quiroga MF, Turk G, Laufer N (2021) Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog 17. https://doi.org/10.1371/journal.ppat.1009161

Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA, Mazzitelli I, di Diego Garcia F, Sanchez L, Rouco SO, Gonzalez Lopez Ledesma MM, Zurano JP, Mazzitelli B, Scruzzi G, Barbero P, Cardozo D, Gallego S, Borda M, Diaz M, Ridao F, Rosales AB, Bhon J, Talia JM, Diangelo ME, Lacaze MA, Aime B, Gutierrez SI, Ercole R, Toro R, Tau L, Delaplace L, Compagnucci MF, Sartori C, Desimone I, Echegoyen C, Velazquez P, Testa C, Hozbor D, Docena G, Laino CH, Kreplak N, Pifano M, Barbas G, Rearte A, Vizzotti C, Castelli JM, Geffner J, Gamarnik AV (2022) Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. Cell Rep Med 3. https://doi.org/10.1016/j.xcrm.2022.100706

Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM (2020) The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 5:1–10. https://doi.org/10.1126/SCIIMMUNOL.ABC8413

Article  Google Scholar 

Pulix M, Lukashchuk V, Smith DC, Dickson AJ (2021) Molecular characterization of HEK293 cells as emerging versatile cell factories. Curr Opin Biotechnol 71:18–24. https://doi.org/10.1016/j.copbio.2021.05.001

Article  CAS  PubMed  Google Scholar 

Rodrigues AF, Soares HR, Guerreiro MR, Alves PM, Coroadinha AS (2015) Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology. Biotechnol J 10:1329–1344. https://doi.org/10.1002/biot.201400387

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwarz H, Zhang Y, Zhan C, Malm M, Field R, Turner R, Sellick C, Varley P, Rockberg J, Chotteau V (2020) Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant erythropoietin. J Biotechnol 309:44–52. https://doi.org/10.1016/j.jbiotec.2019.12.017

Article  CAS  PubMed  Google Scholar 

Shajahan A, Supekar NT, Gleinich AS, Azadi P (2020) Deducing the N- And O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 30:981–988. https://doi.org/10.1093/glycob/cwaa042

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, Mcmahon M, Simon V, Krammer F (2020) SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. https://doi.org/10.1002/cpmc.100

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah J, Devilliers H, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt CE, Mayaux J, Beurton A, Fourati S, Bruel T, Schwartz O, Lacorte JM, Yssel H, Parizot C, Dorgham K, Charneau P, Amoura Z, Gorochov G (2021) IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med 13(577):eabd2223. https://doi.org/10.1126/scitranslmed.abd2223

Townsend JP (2022) The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. 1–8. https://doi.org/10.1073/pnas.2204336119/-/DCSupplemental.Published

Villafañe L, Vaulet LG, Viere FM, Klepp LI, Forrellad MA, Bigi MM, Romano MI, Magistrelli G, Fermepin MR, Bigi F (2022) Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19. J Immunol Methods 500:1–5. https://doi.org/10.1016/j.jim.2021.113182

Article  CAS  Google Scholar 

Volkin DB, Sanyal G, Burke CJ, Middaugh CR (2002) Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals. Pharm Biotechnol 14:1–46

Article  CAS  PubMed  Google Scholar 

WHO (2022) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 10 October 2022.

Wu CR, Yin WC, Jiang Y, Xu HE (2022) Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin 1–13. https://doi.org/10.1038/s41401-021-00851-w

Zhang Y, Zhao W, Mao Y, Chen Y, Zheng S, Cao W, Zhu J, Hu L, Gong M, Cheng J, Yang H (2021) O-Glycosylation landscapes of SARS-CoV-2 spike proteins. Front Chem 9:1–11. https://doi.org/10.3389/fchem.2021.689521

Article  CAS  Google Scholar 

Zhang J, Zhang H, Sun L (2022) Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? MAbs 14(1):2031483. https://doi.org/10.1080/19420862.2022.2031483

Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30:1158–1170. https://doi.org/10.1016/j.biotechadv.2011.08.022

Article  CAS  PubMed  Google Scholar